The Gemini Study was a 14-week, open-label, non-comparative, office-based, multicenter trial to evaluate single-pill therapy in the treatment of concomitant hypertension and dyslipidemia. In addition ...

Screening for cardiovascular risk factors after pregnancy-related hypertension or diabetes may be suboptimal during the year after giving birth, data indicated. In a population-based cohort study that ...

Although screening rates are higher for exposed individuals, rates are low in both exposed and unexposed individuals. (HealthDay News) — Patients with pregnancy-related hypertension (HTN) or diabetes ...

The Vascular Biology and Hypertension Program focuses on molecular and cellular approaches to important problems in cardiovascular medicine. Active in clinical trials include novel therapeutic agents ...

Please provide your email address to receive an email when new articles are posted on . Good response to obesity treatment or achieving remission reduced the risk for cardiovascular outcomes. Obesity ...

Children with metabolically healthy obesity (MHO) have an increased associated risk for cardiometabolic diseases in young adulthood.

Hanmi Pharmaceutical launched the low-dose triple antihypertensive ‘Amoprel’ last August. It has been evaluated as setting a new milestone in the treatment of early-stage hypertension. Developed as ...

Background: Although brain and heart conditions share overlapping risk factors and commonly co-occur, current cardiac and neurologic clinical guidelines are typically produced within specialty silos.